ClinicalTrials.gg
CompletedNCT00925301Updated Oct 30, 2018Results posted

Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease

A Phase 3 interventional study of migalastat hydrochloride and Placebo in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 28 sites in 13 countries. Open to participants aged 16 Years to 74 Years. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
16 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
6th of 20
67 · median 20
Started
2009
the only one that year
Phase 3
11 of 20
2 open now
Registered
6th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 6th largest by enrollment, is the only one that started in 2009, is one of 11 in phase 3, and was the 6th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 16 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

The primary objective of this study was to compare the effect of migalastat (123 milligrams [mg] of migalastat [equivalent to 150 mg of migalastat hydrochloride]) (migalastat) versus placebo on kidney globotriaosylceramide (GL-3).

Read the detailed description

This double-blind, randomized, placebo-controlled study was conducted in 67 participants at 46 sites worldwide. The study consisted of 2 stages and an optional open-label treatment extension phase:

Stage 1 included a screening period of up to 2 months followed by a 6-month treatment period which involved 4 visits to the clinic. Participants were randomized in equal proportions to receive either migalastat or placebo.

After completing the 6-month double-blind phase, all participants entered Stage 2 of the study and received migalastat in an open-label manner. Stage 2 treatment lasted for 6 months and involved up to 4 visits to the clinic.

Participants who completed both Stage 1 and Stage 2 of the study as scheduled were offered the opportunity to participate in an open-label treatment extension phase with migalastat. The open-label treatment extension phase lasted 12 months and involved 2 visits to the clinic. A follow-up visit was undertaken 1 month following completion or discontinuation from the open-label treatment extension. Participants completing the 12-month open-label treatment extension and providing consent to enter a separate long-term extension were not required to complete this follow-up visit.

Study assessments included clinical laboratory tests, 12-lead electrocardiogram, kidney biopsy, kidney function testing, echocardiography, and patient-reported outcomes.

03

Conditions studied

  • Fabry Disease

Browse trials for

Keywords

  • Amicus Therapeutics
  • AT1001
  • Migalastat
  • Pharmacokinetics
  • Substrate
  • Galafold
04

Who can participate

Ages eligible
16 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 16 and 74 diagnosed with Fabry disease.
  • Confirmed mutant form of α-galactosidase A shown to be responsive to migalastat in vitro.
  • Participant has never been treated with enzyme replacement therapy (ERT) or has not received ERT for 6 consecutive months or longer before the screening visit for the study.
  • Urine GL-3 ≥4 times the at screening.
  • Participants taking angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be on a stable dose for a minimum of 4 weeks before the baseline visit.
  • Females who can become pregnant and all males agree to be sexually abstinent or use medically accepted methods of during the study and for 30 days after study completion.
  • Participant is willing and able to provide written and assent, if applicable.

Exclusion criteria

Exclusion Criteria:

  • Participant has undergone or is scheduled to undergo kidney transplantation, or is currently on dialysis.
  • Estimated \<30 milliliters per minute per 1.73 meters squared (chronic kidney disease Stage 4 or 5) based on the Modification of Diet in Renal Disease equation at screening.
  • Pregnant or breast-feeding.
  • History of allergy or sensitivity to study medication (including ) or other iminosugars (for example, miglustat, miglitol).
  • Participant is treated or has been treated with any drug within 30 days of study start.
  • Participant is currently treated or has ever been treated with migalastat.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Migalastat

    Migalastat 150-mg capsule taken orally every other day (QOD) for 6 months and an open-label 6-month treatment extension, followed by an optional, 12-month, open-label treatment extension.

    Drug: migalastat hydrochloride

  • Placebo comparator
    Placebo

    Placebo capsule taken orally QOD for 6 months.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions

    Renal biopsies were taken at Baseline and Month 6 (Stage 1). The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.

    Time frame: Baseline, Month 6

Secondary outcomes

  1. Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6

    Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.

    Time frame: Baseline, Month 6

  2. Change From Baseline Through Month 24 In Urine GL-3 Levels

    The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry. The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE). Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.

    Time frame: Baseline, Months 6, 12, and 24

Other outcomes

  1. Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions

    Renal biopsies were taken at Month 6 and Month 12. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.

    Time frame: Month 6, Month 12

07

Results

Posted Oct 30, 2018
Limitations and caveats
During Phase 3, prior to unblinding, the assay used for enrollment was validated (GLP HEK assay). Mutant forms of α-Gal A that met assay criteria were categorized as amenable; additional analyses were subsequently performed on this target population.

Participant flow

6-Month Double-blind (Stage 1)
Participant flow — 6-Month Double-blind (Stage 1)
MilestoneMigalastat (0-6 Months)Placebo (0-6 Months)Migalastat (>6-12 Months)Migalastat (>12-24 Months)
Started343300
Received at least 1 dose of study drug343300
Intent-to-treat (itt)343300
Modified intent-to-treat (mitt)303000
Completed343000
Not completed0300
Withdrew: Withdrawal by subject0200
Withdrew: Pregnancy0100
6-Month Open-label (Stage 2)
Participant flow — 6-Month Open-label (Stage 2)
MilestoneMigalastat (0-6 Months)Placebo (0-6 Months)Migalastat (>6-12 Months)Migalastat (>12-24 Months)
Started00630
Itt-amenable00470
Completed00600
Not completed0030
Withdrew: Withdrawal by subject0010
Withdrew: Adverse event0020
12-Month Open-label Extension (Optional)
Participant flow — 12-Month Open-label Extension (Optional)
MilestoneMigalastat (0-6 Months)Placebo (0-6 Months)Migalastat (>6-12 Months)Migalastat (>12-24 Months)
Started00057
Itt-amenable00042
Completed00054
Not completed0003
Withdrew: Withdrawal by subject0001
Withdrew: Pregnancy0001
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryPercentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions

Renal biopsies were taken at Baseline and Month 6 (Stage 1). The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. A responder was defined as a participant with a ≥50% reduction from Baseline to Month 6 in the average number of kidney IC GL-3 inclusions.

Time frame:
Baseline, Month 6
Reported as:
Count of participants · Participants
Percentage Of Participants With At Least A 50% Reduction From Baseline To Month 6 In The Average Number Of Kidney Interstitial Capillary (IC) Globotriaosylceramide (GL-3) Inclusions
ParticipantsMigalastatPlacebo
Responder139
Non-Responder1923
Statistical analysis
  • Migalastat vs Placebo · Cochran-Mantel-Haenszel · p = 0.2996 · Difference: 12.5 · 95% CI -13.4 to 37.3The difference between the percentage of successes between migalastat and placebo treatment groups
SecondaryPercent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6

Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images.

Time frame:
Baseline, Month 6
Reported as:
Mean · percent change
Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6
percent changeMigalastatPlacebo
Percent Change In Kidney IC GL-3 Inclusions From Baseline To Month 6-7.948 ± 105.273612.985 ± 90.5131
SecondaryChange From Baseline Through Month 24 In Urine GL-3 Levels

The effect of migalastat versus placebo on urine GL-3 levels was measured by liquid chromatography-mass spectrometry/mass spectrometry. The 24-hour urine samples were collected at Baseline, Month 6 (Stage 1), Month 12 (Stage 2), and Month 24 (OLE). Results are presented as changes in nanograms (ng)/mg creatinine from Baseline to the end of the 3 stages.

Time frame:
Baseline, Months 6, 12, and 24
Reported as:
Mean · ng/mg creatinine
Change From Baseline Through Month 24 In Urine GL-3 Levels
ng/mg creatinineMigalastat-MigalastatPlacebo-Migalastat
Stage 1-234.80 ± 853.451-186.24 ± 957.119
Stage 2-179.63 ± 699.157-537.95 ± 1169.883
OLE-62.37 ± 615.944-177.42 ± 288.224
Other pre-specifiedChange From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions

Renal biopsies were taken at Month 6 and Month 12. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Month 6 and Month 12. Assessments were made using digital images.

Time frame:
Month 6, Month 12
Reported as:
Least squares mean · kidney IC GL-3 inclusions
Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions
kidney IC GL-3 inclusionsPlacebo-Migalastat
Change From Month 6 To Month 12 In Average Number Of Kidney IC GL-3 Inclusions-0.320 (-0.5719 to -0.0677)
Statistical analysis
  • Placebo-Migalastat · MMRM · p = 0.014 (Significant at the 0.050 level)
Post-hocChange From Baseline To Month 6 In Average Number Of Kidney IC GL-3 Inclusions

Renal biopsies were taken at Baseline and Month 6. The specimens were evaluated using virtual microscopy. The annotation, scoring, and adjudication of the kidney histology assessments were performed by the Clinical Pathology Endpoints Committee. The number of kidney IC GL-3 inclusions was assessed by 3 renal pathologists who were blinded to treatment assignments, participants' data, and biopsy sequence. One pathologist served as annotator and identified the 300 capillaries on up to 8 slides per specimen to be scored. Two pathologists served as scorers; these pathologists completed the blinded paired assessments. Each pathologist served as annotator/adjudicator for 1/3 of the cases. Paired assessments were undertaken at Baseline and Month 6. Assessments were made using digital images. Treatment effect was estimated using the LS mean difference between treatments within the context of the ANCOVA model.

Time frame:
Baseline, Month 6
Reported as:
Mean · kidney IC GL-3 inclusions
Change From Baseline To Month 6 In Average Number Of Kidney IC GL-3 Inclusions
kidney IC GL-3 inclusionsMigalastat
Change From Baseline To Month 6 In Average Number Of Kidney IC GL-3 Inclusions-0.250 ± 0.5126
Statistical analysis
  • Migalastat · ANCOVA · p = 0.0078 (Significant at the 0.010 level) · Difference lsmeans: -0.3 · 95% CI -0.6 to -0.1

Adverse events

Collected over Adverse events (AEs) were monitored up to 25 months (±7 days) after the first dose of study drug. AEs were reported from the first dose of study medication at Baseline (Visit 1) in Stage 1 to 1 month (±7 days) after the date of the last study visit, whether during Stage 1, Stage 2, or the optional OLE, or after premature discontinuation from the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Migalastat (0-6 Months)—2/34 (5.9%)31/34 (91.2%)
Placebo (0-6 Months)—4/33 (12.1%)30/33 (90.9%)
All Migalastat (>6-12 Months)—5/63 (7.9%)50/63 (79.4%)
All Migalastat (>12-24 Months)—11/57 (19.3%)46/57 (80.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventMigalastat (0-6 Months)Placebo (0-6 Months)All Migalastat (>6-12 Months)All Migalastat (>12-24 Months)
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/340/332/630/57
Post Procedural HaemorrhageInjury, poisoning and procedural complications0/341/330/630/57
Anaplastic Large Cell Lymphoma T - and Null - Cell TypesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/341/330/630/57
Bacterial InfectionInfections and infestations0/341/330/630/57
Meningitis ViralInfections and infestations0/341/330/630/57
Post Procedural HaematomaInjury, poisoning and procedural complications1/340/330/630/57
HydronephrosisRenal and urinary disorders1/340/330/630/57
Multiple FracturesInjury, poisoning and procedural complications0/340/330/631/57
PalpitationsCardiac disorders0/340/330/631/57
PneumothoraxRespiratory, thoracic and mediastinal disorders0/340/330/631/57
Most frequent other events
Showing 10 of 41
Most frequent other events
EventMigalastat (0-6 Months)Placebo (0-6 Months)All Migalastat (>6-12 Months)All Migalastat (>12-24 Months)
HeadacheNervous system disorders12/347/339/636/57
NasopharyngitisInfections and infestations6/342/335/633/57
ProteinuriaRenal and urinary disorders0/340/331/639/57
FatigueGeneral disorders4/344/332/633/57
ParaesthesiaNervous system disorders4/344/334/632/57
Pain In ExtremityMusculoskeletal and connective tissue disorders0/344/332/632/57
PyrexiaGeneral disorders4/341/331/630/57
NauseaGastrointestinal disorders4/342/332/633/57
Procedural PainInjury, poisoning and procedural complications2/341/337/630/57
BronchitisInfections and infestations1/340/331/636/57

Baseline characteristics

Safety Population: All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Migalastat-MigalastatPlacebo-MigalastatTotal
Mean40.0 ± 13.2944.5 ± 10.1842.2 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)Migalastat-MigalastatPlacebo-MigalastatTotal
Female222143
Male121224
08

Study locations

28 sites
  • Los Angeles, California 90048, United States
  • San Francisco, California 94143, United States
  • Decatur, Georgia 30033, United States
  • Chicago, Illinois 60611, United States
  • Kansas City, Kansas 66160, United States
  • Boston, Massachusetts 02114, United States
  • Grand Rapids, Michigan 49525, United States
  • New York, New York 10032, United States
  • Pittsburgh, Pennsylvania 15224, United States
  • Dallas, Texas 75226, United States
  • Salt Lake City, Utah 84132, United States
  • Springfield, Virginia 22152, United States
  • Seattle, Washington 98195, United States
  • Buenos Aires, B1629ODT, Argentina
  • Adelaide, 5006, Australia
  • Parkville, 3050, Australia
  • Porto Alegre, 90035-903, Brazil
  • Sao Paulo, 14048-900, Brazil
  • Montreal, Quebec H4J 1C5, Canada
  • Kobenhavn, DK-2100, Denmark
  • Cairo, 11451, Egypt
  • Garches, 92380, France
  • Roma, 00168, Italy
  • Warszawa, 04-628, Poland
  • Barcelona, 08025, Spain
  • Zaragoza, 50009, Spain
  • Ankara, 06500, Turkey
  • Salford, M6 8HD, United Kingdom
09

References and documents

Publications

  • Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, Krusinska E, Schiffmann R. Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021 Jan;23(1):192-201. doi: 10.1038/s41436-020-00968-z. Epub 2020 Sep 30. Erratum In: Genet Med. 2021 Jan;23(1):238. doi: 10.1038/s41436-020-01041-5. PubMed 32994552 ↗
  • Germain DP, Nicholls K, Giugliani R, Bichet DG, Hughes DA, Barisoni LM, Colvin RB, Jennette JC, Skuban N, Castelli JP, Benjamin E, Barth JA, Viereck C. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019 Sep;21(9):1987-1997. doi: 10.1038/s41436-019-0451-z. Epub 2019 Feb 6. PubMed 30723321 ↗
  • Schiffmann R, Bichet DG, Jovanovic A, Hughes DA, Giugliani R, Feldt-Rasmussen U, Shankar SP, Barisoni L, Colvin RB, Jennette JC, Holdbrook F, Mulberg A, Castelli JP, Skuban N, Barth JA, Nicholls K. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018 Apr 27;13(1):68. doi: 10.1186/s13023-018-0813-7. PubMed 29703262 ↗
  • Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22. PubMed 27657681 ↗
  • Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198. PubMed 27509102 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Jun 2012, 31 months.

Results were first posted in Oct 2018, 6 years 4 months after primary completion. A results delay was requested in Sep 2013.

Of 22 phase 3 interventional studies under Fabry Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 64. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2009
First posted
Jun 22, 2009
StartActual
Oct 23, 2009
Primary completionActual
Jun 12, 2012
CompletionActual
Jan 29, 2014
Results delay requested
Sep 25, 2013
Results first posted
Oct 30, 2018
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00925301
Responsible party
Sponsor
First posted
Jun 22, 2009
Start date
Oct 23, 2009
Primary completion
Jun 12, 2012
Completion
Jan 29, 2014
Results posted
Oct 30, 2018
Last update
Oct 30, 2018

Study contacts

Medical Monitor, Clinical Research
study director · Amicus Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion